SCHEMBL88871

SCHEMBL88871

C=CCOC(=O)N(C)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 1/20 0.54
▸ CHRNB4 P30926 1/20 0.54
▸ CHRNA3 P32297 1/20 0.54
▸ CHRNA4 P43681 1/20 0.54
▸ CYP3A4 P08684 1/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ MEN1 O00255 5/20 0.44
▸ KMT2A Q03164 5/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ PKM P14618 1/20 0.43
▸ LMNA P02545 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062715 0.85 ALDH1A1 (0.45) CHRNB2CHRNB4CHRNA3CHRNA4CYP3A4
SCHEMBL2485044 0.84 CYP3A4 (0.47) CHRNB2CHRNB4CHRNA3CHRNA4CYP3A4
SCHEMBL13393309 0.84 CHRNB2 (0.58) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL515011 0.81 CHRNB2 (0.58) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL8023793 0.80 CYP3A4 (0.50) CYP3A4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4557752 0.80 CYP3A4 (0.50) CYP3A4SMN1; SMN2RAB9AALDH1A1NPC1
Benzene SCHEMBL1720409 0.79 CHRNB2 (0.59) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL442790 0.79 CHRNB2 (0.59) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL9597461 0.78 CYP3A4 (0.47) CYP3A4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL9304637 0.78 CYP3A4 (0.47) CYP3A4SMN1; SMN2RAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618162-B2 Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (AChE) VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2013-12-31 — — US disclosed
US-20120122970-A1 INSECTICIDAL CARBAMATES EXHIBITING SPECIES-SELECTIVE INHIBITION OF ACETYLCHOLINESTERASE (AChE) VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY 2012-05-17 — — US disclosed
US-8129428-B2 Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (AChE) VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2012-03-06 — — US disclosed
WO-2009036235-A2 INSECTICIDAL CARBAMATES EXHIBITING SPECIES-SELECTIVE INHIBITION OF ACETYLCHOLINESTERASE (ACHE) VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2009-03-19 — — WO disclosed
US-20090068242-A1 INSECTICIDAL CARBAMATES EXHIBITING SPECIES-SELECTIVE INHIBITION OF ACETYLCHOLINESTERASE (AChE) VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY 2009-03-12 — — US disclosed
US-3992455-A CHEMICAL INTERMEDIATES FOR INSECTICIDES KOPPERS COMPANY, INC. (US) 1976-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068242-A1 INSECTICIDAL CARBAMATES EXHIBITING SPECIES-SELECTIVE INHIBITION OF ACETYLCHOLINESTERASE (AChE) ACHE, BCHE, CHAT CHRNB2 96/4885CHRNB4 144/4885CHRNA3 53/4885
US-20120122970-A1 INSECTICIDAL CARBAMATES EXHIBITING SPECIES-SELECTIVE INHIBITION OF ACETYLCHOLINESTERASE (AChE) ACHE, BCHE, CHAT CHRNB2 96/4885CHRNB4 144/4885CHRNA3 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback